A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Vantictumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 23 Jul 2019 Results published in the Investigational New Drugs
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
- 08 May 2017 Status changed from active, no longer recruiting to suspended, according to an OncoMed Pharmaceuticals media release.